Cupid Limited Receives CE (EU IVDR) Certification for HIV 1and2 and Hepatitis B IVD Test Kits, Expanding Global Market Access in Diagnostics

Cupid Limited, (BSE – 530843, NSE – CUPID), a diversified Indian healthcare and consumer products company with a growing focus on in-vitro diagnostics (IVD),wellness, and personal care, announced that it has received CE (EU IVDR) Certification for two in-vitro diagnostic (IVD) products – the CupiKIT HIV 1&2 Antibody Test Kit and the CupiKITHepatitis B Surface Antigen (HBsAg) Test Kit. The certifications […]

Continue Reading

Cupid Limited Delivers Record Q3 FY26 Performance with 201 percent YoY Growth in EBITDA

Mumbai (Maharashtra) [India], January 30: Cupid Limited (Cupid, The Company), announced that it delivered the strongest quarter in its history during Q3 FY26 (quarter ended 31 December 2025), driven by strong execution, healthy demand, and sustained momentum across its businesses. The Company continues to witness strong operating traction, with both Q3 and Q4 FY26 tracking at a higher run-rate, […]

Continue Reading